Leidos secures prime contract with ARPA-H to propel biomedical breakthroughs

Leidos (NYSE:LDOS), a renowned Fortune 500 innovation company, has recently been awarded a prime contract by the Advanced Research Projects Agency for Health (ARPA-H). This hybrid firm fixed price/time and materials contract, issued by the U.S. Department of Health and Human Services (HHS), includes a one-year base period of performance with two one-year options. This partnership is set to make significant strides in the health sector, particularly in biomedical research and groundbreaking health discoveries.

Liz Porter, President of the Health and Civil Sector at Leidos, expressed enthusiasm about the collaboration: “We are thrilled to work with ARPA-H building the infrastructure and capabilities necessary to drive biomedical breakthroughs and groundbreaking health discoveries.” Porter emphasizes Leidos’ commitment to leveraging its expertise in health solutions to support ARPA-H’s growth and mission.

ARPA-H, an independent entity of the National Institutes of Health (NIH), focuses on developing high-impact transformative biomedical and health research. Through this contract, Leidos will provide scalable solutions and resilient systems, enhancing ARPA-H’s mission to accelerate better health outcomes for everyone. This includes a comprehensive range of IT support, alongside the design, development, and implementation of cutting-edge solutions.

ARPA-H Chooses Leidos for Innovative Health Solutions, Enhancing Biomedical Research

In a related development, Leidos announced the successful deployment of a new Flight Service Voice Communications System (FSVCS) using Voice over Internet Protocol (VoIP) technology, in coordination with Rohde & Schwarz USA. This pioneering system, which is the first ED-137C compliant system in the U.S. National Airspace, represents a significant technological advancement. The FSVCS’ network-centric approach, developed for the Future Flight Services Program (FFSP), offers a flexible and scalable solution, integrating both legacy analog connections and new digital voice communication. This innovative design reduces dependency on traditional communication systems and enhances voice availability within the general aviation community.

Leidos’ contract with ARPA-H represents a pivotal moment in the intersection of technology and healthcare. This collaboration is not just a step forward for Leidos but a leap for biomedical research and health outcomes. By combining Leidos’ expertise in IT and health solutions with ARPA-H’s mission, this partnership could lead to significant advancements in tackling some of the most pressing health challenges today. Furthermore, Leidos’ recent success with the FSVCS using VoIP technology showcases its capability to innovate across various sectors, solidifying its position as a leader in technological solutions.